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Relative effectiveness of insulin pump treatment over multiple daily 
injections and structured education during flexible intensive insulin 
treatment for type 1 diabetes: cluster randomised trial (REPOSE)
ABSTRACT
ObjeCtive
To compare the effectiveness of insulin pumps with 
multiple daily injections for adults with type 1 
diabetes, with both groups receiving equivalent 
training in flexible insulin treatment.
Design
Pragmatic, multicentre, open label, parallel group, 
cluster randomised controlled trial (Relative 
Effectiveness of Pumps Over MDI and Structured 
Education (REPOSE) trial).
setting
Eight secondary care centres in England and Scotland.
PartiCiPants
Adults with type 1 diabetes who were willing to 
undertake intensive insulin treatment, with no 
preference for pumps or multiple daily injections. 
Participants were allocated a place on established 
group training courses that taught flexible intensive 
insulin treatment (“dose adjustment for normal 
eating,” DAFNE). The course groups (the clusters) were 
then randomly allocated in pairs to either pump or 
multiple daily injections.
interventiOns
Participants attended training in flexible insulin 
treatment (using insulin analogues) structured around 
the use of pump or injections, followed for two years.
Main OutCOMe Measures
The primary outcomes were a change in glycated 
haemoglobin (HbA1c) values (%) at two years in 
participants with baseline HbA1c value of ≥7.5% 
(58 mmol/mol), and the proportion of participants 
achieving an HbA1c value of <7.5%. Secondary 
outcomes included body weight, insulin dose, and 
episodes of moderate and severe hypoglycaemia. 
Ancillary outcomes included quality of life and 
treatment satisfaction.
results
317 participants (46 courses) were randomised (156 
pump and 161 injections). 267 attended courses and 
260 were included in the intention to treat analysis, 
of which 235 (119 pump and 116 injection) had 
baseline HbA1c values of ≥7.5%. Glycaemic control 
and rates of severe hypoglycaemia improved in both 
groups. The mean change in HbA1c at two years was 
−0.85% with pump treatment and −0.42% with 
multiple daily injections. Adjusting for course, centre, 
age, sex, and accounting for missing values, the 
difference was −0.24% (−2.7 mmol/mol) in favour of 
pump users (95% confidence interval −0.53 to 0.05, 
P=0.10). Most psychosocial measures showed no 
difference, but pump users showed greater 
improvement in treatment satisfaction and some 
quality of life domains (dietary freedom and daily 
hassle) at 12 and 24 months.
COnClusiOns
Both groups showed clinically relevant and long 
lasting decreases in HbA1c, rates of severe 
hypoglycaemia, and improved psychological 
measures, although few participants achieved glucose 
levels currently recommended by national and 
international guidelines. Adding pump treatment to 
structured training in flexible intensive insulin 
treatment did not substantially enhance educational 
benefits on glycaemic control, hypoglycaemia, or 
psychosocial outcomes in adults with type 1 diabetes. 
These results do not support a policy of providing 
insulin pumps to adults with poor glycaemic control 
until the effects of training on participants’ level of 
engagement in intensive self management have been 
determined.
trial registratiOn
Current Controlled Trials ISRCTN61215213.
Introduction
People with type 1 diabetes mellitus require lifelong 
treatment with insulin to prevent diabetic ketoacidosis 
and to optimise blood glucose levels to minimise vascu-
lar complications.1  Insulin is generally administered by 
multiple daily subcutaneous injections, using different 
insulins to cover background and meal requirements. 
Doses are adjusted according to eating, physical activ-
ity, and blood glucose level. This approach and its inte-
gration within flexible lifestyles is promoted in “dose 
adjustment for normal eating” (DAFNE)2  and similar 
structured training courses.3  Despite this training and 
WhAT IS AlReAdy knoWn on ThIS TopIC
Assessments of insulin pump treatment in type 1 diabetes concluded that it was 
worthwhile for those who were otherwise unable to achieve good glycaemic control 
without disabling hypoglycaemia
The case for wider use is uncertain, given the small size and short duration of trials 
of pumps versus modern multiple daily injections, and the need to distinguish the 
effects of the pump and the extra education provided
WhAT ThIS STudy AddS
The REPOSE trial randomised patients to pump or multiple daily injections, with 
both groups receiving similar structured education; HbA1c levels and rates of severe 
hypoglycaemia decreased in both groups, slightly more in the pump group, but 
without statistical significance
Both groups showed improved quality of life benefits, but those using pumps 
showed additional albeit modest benefits in quality of life, reported fewer 
restrictions in diet and daily hassles in the diabetes specific quality of life scale, 
and greater treatment satisfaction
Although participation in the courses produced sustained improvement, levels of 
glucose control remained far short of those currently recommended by NICE
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best efforts, many people struggle to achieve glycaemic 
targets and a considerable proportion go on to develop 
serious complications, reducing both the length and 
the quality of their lives.1 4
In continuous subcutaneous insulin infusion, a 
pump delivers insulin continuously under the skin 
through a small plastic tube and cannula.5 6 Pumps are 
filled with quick acting insulin to supply both back-
ground insulin and insulin replacement after meals.
Potential advantages include more precise insulin 
delivery and the ability to adjust basal insulin levels. 
Observational studies have reported improved glucose 
control, reduced risk of hypoglycaemia, and enhanced 
quality of life. Pump treatment is more expensive than 
multiple daily injections, with pumps costing around 
£2500 ($3041; €2800) each plus £1500 a year for con-
sumables (cannulas, reservoirs, and batteries).7
In the UK, pump use is approved in adults with type 1 
diabetes who have high glycated haemoglobin (HbA1c) 
values (>8.5%) or an inability to achieve reasonable 
control without “disabling hypoglycaemia.”8  An esti-
mated 6% of UK adults with type 1 diabetes use pumps, 
which is lower than in many comparable countries.9 
Around 40% of people with type 1 diabetes in the USA 
use pumps,10  and proponents of pumps suggest that far 
more people should be offered them in the UK.11
One weakness of existing evidence is that patients 
allocated to pumps are likely to have received more 
training and attention than those using multiple daily 
injections. A recent observational study12 of pump treat-
ment and injections, where both groups received inten-
sive education in insulin usage, concluded that the 
training might have made the most difference. To our 
knowledge, no randomised trials in adults have com-
pared pump treatment with multiple daily injections 
where the same structured training in insulin adjust-
ment has been provided, so the added benefit of pump 
technology remains unclear.
In the Relative Effectiveness of Pumps Over MDI and 
Structured Education (REPOSE) trial we assessed the 
effectiveness of adding pump treatment to high quality 
equivalent structured education in flexible intensive 
insulin treatment for people with type 1 diabetes, com-
paring pump plus education with multiple daily injec-
tions plus education. Our hypothesis was that much of 
the benefit of pump treatment might come from the 
re-training and education in insulin use given to enable 
patients to use pumps safely. We present the clinical 
effectiveness and quantitative psychosocial results of 
this pragmatic trial.
Methods
trial design
The study protocol has been previously published.13 In 
brief, we conducted a multicentre, parallel group, open 
label, confirmatory, cluster randomised controlled trial. 
Eight secondary care centres (three in Scotland and five 
in England) recruited up to 40 participants to three 
pump and three multiple daily injection courses (with 
five to eight patients on each course) over 11 months. 
Participants were allocated a place on a one week 
DAFNE skills training course, with a further visit at six 
weeks. The course groups (clusters) were randomly 
allocated in pairs to either pump or multiple daily injec-
tions. After the courses, participants received the trial 
treatment for two years. We collected outcome mea-
sures at baseline (up to three weeks before the DAFNE 
course) and at six, 12, and 24 months. A cluster design 
was chosen to address the challenge of randomising 
participants and then finding suitable times for their 
attendance on a course of the correct allocation. We 
believe this approach reduced both recruitment bias 
and attrition rates before the course.
Participants
We recruited adults with a diagnosis of type 1 diabetes 
for at least 12 months, and who were willing to under-
take intensive insulin treatment with self monitoring of 
blood glucose levels, counting of carbohydrate intake, 
and insulin self adjustment, with no preference for 
either pump or multiple daily injections. Participants 
were those with clinical indications for structured edu-
cation in insulin treatment to optimise diabetes control 
who had not participated previously in structured train-
ing. We excluded those with a strong desire for pump 
treatment, those already using optimised multiple daily 
injections and meeting the criteria of the National Insti-
tute for Health and Care Excellence for pump treatment, 
those needing a pump in the opinion of the investigator, 
those with serious diabetic complications, and those 
unable to communicate in English. Courses (clusters) 
required between five and eight participants to main-
tain optimal course dynamics.
interventions
Participants using multiple daily injections attended 
standard DAFNE structured education courses,2  which 
were conducted over five consecutive days and deliv-
ered to groups of five to eight adults as outpatients. The 
participants took insulin aspart, a quick acting insulin 
analogue, for meals, and twice daily injections of insu-
lin detemir for background replacement. They used the 
Accu-Chek Aviva Expert Bolus Advisor System (Roche 
Diagnostics Ltd, Burgess Hill, UK) as a bolus calculator, 
as there is evidence that bolus advisers can improve gly-
caemic control, presumably by helping patients calcu-
late the appropriate meal related bolus.14
Participants allocated to pump treatment attended a 
modified DAFNE course, previously validated in pump 
users.15 That course maintained the five day structure 
and the principles of insulin dose adjustment in the 
standard DAFNE course, but also incorporated the prac-
tical skills and learning outcomes needed to use pumps 
successfully. This necessitated an additional group ses-
sion, delivered one to three weeks before the main 
course. Standard DAFNE includes a rigorous quality 
assurance programme. For the pump courses, fidelity 
testing was undertaken to assess incorporation of 
appropriate pump training. Participants used a Min-
imed Paradigm Veo insulin pump (model X54; 
Medtronic, Watford, UK) with insulin aspart. The bolus 
wizard in the pumps was activated as part of the course.
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The curriculum (and associated patient workbook) 
was adapted specifically to make better use of pump 
features, compared with standard (multiple daily injec-
tions) DAFNE. This included general pump manage-
ment (infusion sets, cannulas, filling reservoirs, 
changing batteries, and troubleshooting). During the 
five day course participants were also taught use of the 
bolus wizard, basal testing and adjustment (including 
fasting during the day and overnight glucose profiles), 
use of temporary basal rates for physical activity or 
alcohol intake (reduced) and illness (increased), use of 
alternative bolus “waves” (extended, multiwave), pre-
vention of diabetic ketoacidosis (“sick day rules” eg, 
when to use a pen to inject insulin in case of cannula/
pump failure, how much insulin to give and how often).
All participants (multiple daily injections and contin-
uous subcutaneous insulin infusion) were invited to the 
course follow-up session at six to eight weeks, and 
those who required additional input were offered fur-
ther one-to-one appointments. These appointments 
were supported by meter or pump downloads (Diasend: 
www.glooko.com/diasend; CareLink: www.medtronic-
diabetes.com/products/carelink-personal-diabe-
tes-software), depending on local availability. 
Participants were encouraged to maintain paper record 
diaries to facilitate discussion and adjustments, accord-
ing to the principles taught on the course and supported 
by the workbook. Some might have already sought 
additional help in between these planned appoint-
ments. We recorded diabetes related contact with edu-
cators outside the course and at the six week follow-up.
Outcomes
Primary outcomes
We specified two primary outcomes. One was the 
change in HbA1c (%, measured centrally) after two 
years in participants whose baseline HbA1c was ≥7.5% 
(58 mmol/mol). HbA1c is the accepted ideal surrogate 
measure of glycaemic control and provides a measure 
of efficacy and a means of modelling long term cost 
effectiveness. Our choice of this primary outcome was 
based on our concern that HbA1c values might not 
decrease in those who entered the trial with low base-
line values, but who might be experiencing problematic 
hypoglycaemia. Success for such individuals would be 
an HbA1c value that was maintained or even increased 
but with a reduced frequency of severe hypoglycaemia 
(an important secondary endpoint).
The other primary endpoint was the proportion of 
participants reaching the 2004 NICE target of HbA1c 
≤7.5% (58 mmol/mol).
Secondary outcomes
Secondary biomedical outcomes measured at six, 12, 
and 24 months were moderate hypoglycaemia (an epi-
sode that could be treated by the individual, but where 
hypoglycaemia caused a significant interruption of cur-
rent activity leading to impaired performance, or 
embarrassment, or being woken during nocturnal 
sleep); severe hypoglycaemia (an episode leading to 
cognitive impairment sufficient to cause either coma or 
requiring the assistance of another person to recover); 
total and high density lipoprotein cholesterol levels; 
proteinuria; insulin dose; and body weight. Diabetic 
ketoacidosis was recorded through the assessment of 
serious adverse events throughout the trial.
Ancillary outcomes
Quantitative psychosocial self completed question-
naires assessed generic and diabetes specific quality of 
life: SF-12 (12 item short form health survey); WHO-
QOL-BREF (World Health Organization quality of life–
BREF); EQ-5D (EuroQol five dimensions questionnaire); 
DSQOL (diabetes specific quality of life), fear of hypo-
glycaemia (HFS: hypoglycaemia fear scale), satisfaction 
with treatment (DTSQ: diabetes treatment satisfaction 
questionnaire), and emotional wellbeing (HADS: hospi-
tal anxiety and depression scale) at the same time 
points.13
A health economic evaluation to address the ques-
tion “What is the cost effectiveness of pump treatment 
compared with multiple daily injections in patients 
receiving the DAFNE structured education pro-
gramme?” was undertaken. It has been submitted for 
publication. It included a within trial and a modelled 
patient lifetime analysis, the latter being the primary 
focus of the evaluation.
sample size
We calculated the sample size using a minimally clini-
cally important difference of 0.5% (5.5 mmol/mol) in 
HbA1c values. To detect this difference with a standard 
deviation of 1% at 80% power and 5% two sided signif-
icance required 64 participants with an HbA1c of ≥7.5% 
in each group. To allow for clustering of educators, an 
average of seven participants per group, a within course 
intraclass correlation coefficient of 0.05, and a 10% 
dropout rate, we required a sample size of 93 in each 
group. In the DAFNE database,15 75% of participants 
had an HbA1c value ≥7.5%, so we required 124 partici-
pants per group. We planned to recruit 280 partici-
pants, which increased the power to 85% but allowed 
for some variation in dropout rates and the proportion 
of participants with HbA1c of ≥7.5%. However, monitor-
ing of baseline data showed the actual proportion of 
participants with an HbA1c of ≥7.5% was around 90%. 
A modelling exercise undertaken during recruitment 
with conservative estimates of 85% (HbA1c ≥7.5%) and 
dropout rate of 15% suggested the trial would require at 
least 240 participants with primary outcome data at two 
years to preserve a power of at least 85%.
randomisation
After providing consent, participants were allocated to a 
training course, depending on their availability. Courses 
were randomised in pairs either to DAFNE plus pump or 
to DAFNE plus multiple daily injections. Simple rando-
misation in a block size of two, stratified by centre, was 
used for the first four courses. Courses 5 onwards were 
allocated in pairs using minimisation; the number of 
participants with baseline HbA1c values ≥7.5% and the 
total number of participants were used as minimisation 
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factors. A statistician within Sheffield Clinical Trials 
Research Unit conducted the randomisation by a user 
written Stata code produced to generate allocation. The 
trial coordinator revealed the allocation to study sites. 
Participants who were unable to attend their original 
course were allowed to attend a later course in the same 
treatment arm, to reduce selection bias.
statistical analysis
Analyses were performed in Stata 13 after a prespecified 
approved statistical analysis plan. All analyses were by 
intention to treat, with participants analysed in the 
groups to which they were randomised, unless other-
wise specified. Participants were included in the inten-
tion to treat analysis if they had at least one 
post-baseline HbA1c measure. Those who dropped out 
before receiving the intervention were substituted 
where possible, to ensure the courses were run with 
adequate numbers of participants, but these individu-
als were not included in the analysis. Statistical tests 
were two sided at the 5% significance level.
We analysed the change in HbA1c (%) at two years 
using a mixed effects model, with centre and baseline 
HbA1c treated as fixed effect covariates, and course 
(cluster) as a random intercept. For the primary analy-
sis we used multiple imputation to impute missing 
HbA1c data for participants with at least one follow-up 
HbA1c measure but without two years outcome. We also 
performed a per protocol sensitivity analysis that 
excluded participants who had switched treatment. 
Changes in HbA1c values at six months and one year 
were analysed in the same way.
The proportion of participants reaching an HbA1c of 
<7.5% was compared between groups using a logistic 
regression model adjusted for baseline HbA1c, and cen-
tre and modelling separate courses within centre as 
random intercepts.
We used negative binomial mixed effects regression 
(to account for over-dispersion and clustering) on the 
number of moderate hypoglycaemic episodes in the 
four weeks before each follow-up, and occurrence of at 
least one moderate episode in the four weeks before 
courses as a covariate and the same covariates 
described previously. The number of severe hypoglycae-
mic episodes in two years was analysed as for moderate 
hypoglycaemic episodes, with the addition of study fol-
low-up as the exposure. Incidence rate ratios were cal-
culated using negative binomial random effects 
regression with participant as the random effect, 
adjusted for baseline HbA1c value and centre, based on 
the full intention to treat set (n=260).
Secondary continuous outcomes (insulin dose, body 
weight, high density lipoprotein and total cholesterol 
levels) were analysed as for the primary outcome. We 
categorised proteinuria as macroalbuminuria, microal-
buminuria, or normal and analysed using mixed effects 
ordered logistic regression adjusted for clustering by 
course (random effect), centre, and baseline HbA1c 
(fixed effects).
Changes in psychological outcomes were analysed 
using a mixed model adjusted for course (random), 
 centre, baseline HbA1c, and baseline score, with the 
exception of the diabetes treatment satisfaction 
questionnaire, which we compared between groups 
using a non-parametric Wilcoxon-Mann-Whitney U 
test. No adjustments for multiple testing were made 
to the significance level for all exploratory secondary 
objectives.
A retrospective subgroup analysis used mixed effects 
regression modelling with the primary outcome, 
change in HbA1c (%), including main effects of treat-
ment group and subgroup, an interaction term between 
treatment and subgroup, and covariates of centre (fixed 
effect) and course (random effect). All categories for the 
subgroup analysis were prespecified in the statistical 
analysis plan but not in the original protocol, and are 
reported in full.
Patient involvement
Fifteen people, who had previously attended DAFNE 
courses (including pilot courses on pump treatment) 
but were not participating in the trial, were recruited to 
act as a user group and contribute to different aspects of 
the work. We invited two members to join both the 
steering group and the other investigator meetings. In 
addition, one of the project team (a doctor) is a pump 
user. They provided input to the trial design, implemen-
tation, and dissemination, including all participant 
materials. This included a discussion of the most appro-
priate research questions and whether individuals who 
were willing to try pump treatment could be success-
fully recruited into a trial where they could be ran-
domised to multiple daily injections.
Results
study participants
Participants were recruited between November 2011 
and April 2013. Follow-up continued until June 2015. 
The CONSORT flowchart (fig 1) shows the flow of 
patients through the trial. Forty six courses were ran-
domised. Of the 317 participants included in the rando-
misation, 50 were excluded from any analysis; 40 
withdrew before giving baseline data and 10 before 
their course. All randomised courses were delivered. Of 
267 participants randomised and attending the baseline 
assessment and the course, 260 (pump=132; 
 injections=128) made up the intention to treat set. Two 
hundred and forty eight participants had complete pri-
mary outcome data at 24 months.
Table 1 shows the baseline demographics and char-
acteristics of the trial population stratified by treatment 
received. Baseline data were well balanced between 
treatment groups, with the exception of slightly higher 
baseline HbA1c in the pump group (9.3% v 9.0%). Just 
9% had a baseline HbA1c <7.5%.
Primary outcomes
HbA1c
At 24 months in participants whose baseline HbA1c 
was ≥7.5% (n=119 in pump group; n=116 in multiple 
daily injections group) the mean change in the pump 
group was a decrease of 0.85% (9.3 mmol/mol) 
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 compared with 0.42% (4.5 mmol/mol) in the multiple 
daily injections group. After adjusting for centre, 
course, and baseline HbA1c, the mean difference in 
HbA1c change from baseline was −0.24% (95% confi-
dence interval −0.53% to 0.05%) (−2.7 mmol/mol, −5.8 
to 0.5) in favour of pump treatment (P=0.10). The treat-
ment difference was larger for the per protocol analy-
sis; mean difference −0.36% (−0.64% to −0.07%) (−3.9 
mmol/mol, −7.0 to −0.8) in favour of pump treatment 
(P=0.02), although this point estimate was still smaller 
than the prespecified minimal clinically important dif-
ference. Estimate of the intraclass correlation coeffi-
cient was approximately 0.5%.
At 24 months, for the treatment groups combined 
(n=248), in all participants with complete HbA1c data 
there was a decrease of 0.54% (95% confidence interval 
0.38% to 0.69%) (5.9 mmol/mol, 4.2 to 7.6) and for par-
ticipants with baseline HbA1c ≥7.5% (n=224) the 
decrease was slightly greater, at 0.64% (95% confidence 
interval 0.48% to 0.80%) (7 mmol/mol, 5.2 to 8.8).
Proportion of participants reaching HbA1c ≤7.5%  
(58 mmol/mol)
The proportions of participants reaching an HbA1c 
≤7.5% (58 mmol/mol) after two years, regardless of 
baseline HbA1c value, were 25.0% for the pump group 
and 23.3% for the multiple daily injections group 
(odds ratio 1.22, 95% confidence interval 0.62 to 2.39, 
P=0.57, table 2). The results were similar at six and 
12 months.
The primary analysis at 24 months was repeated for 
six and 12 month follow-up visits (table 3). The results 
for these interim time points were consistent with the 
primary outcome analysis. The largest difference in 
HbA1c change from baseline was observed at six 
months, with an adjusted mean difference of −0.25% 
(95% confidence interval −0.52% to 0.02%) (−2.7 mmol/
mol, −5.6 to 0.2), P=0.07. Figure 2 displays the change in 
HbA1c for participants with data at all four time points 
by treatment group.
MDI (n=161) Pump (n=156)
Invited to take part (n=1278) 
Non-responders (n=393; 31%)
Responders (n=885; 69%)
Not interested (n=523; 59%)
Dropped out prior to baseline (n=17) Dropped out prior to baseline (n=23)
Baseline data (n=138)Baseline data (n=139)
6 month follow-up data (n=123)
(5 continuing in study, missing HbA1c)
12 month follow-up data (n=120)
(5 continuing in study, missing HbA1c)
12 month follow-up data (n=126)
(4 continuing in study, missing HbA1c)
6 month follow-up data (n=132)
24 month follow-up data (n=128) 24 month follow-up data (n=120)
Course attendees (n=135)
Baseline questionnaires completed (n=132) 
Courses (n=23)
Course attendees (n=132)
Baseline questionnaires completed (n=132) 
Courses (n=23)
Dropped out prior to DAFNE (n=7) Dropped out prior to DAFNE (n=3)
Eligible (n=334; 92%)
Eligible but not consented  (n=13; 4%)
Eligible and consented to take part  (n=321; 96%)
Randomised (n=317)
Dropped out prior to randomisation (n=4)
Interested to take part (n=362; 41%)
Ineligible (n=19; 5%)
Not screened (n=9; 2%)
Fig 1 | COnsOrt flowchart for rePOse cluster randomised trial to compare the 
effectiveness of insulin pumps with multiple daily injections (MDi). DaFne=dose 
adjustment for normal eating
table 1 | baseline demographics of trial population. values are numbers (percentages) unless stated otherwise
Characteristics
Pump treatment  
(n=132)
Multiple daily injections 
(n=135) total (n=267)
Mean (SD) age (years), range 41.5 (14.2), 18.5-77.6 39.9 (12.5), 18.5-73.1 40.7 (13.4), 18.5-77.6
Men 78 (59) 82 (61) 160 (60)
White British 125 (95) 119 (88) 244 (91)
Mean (SD) body mass index, range 27.4 (5.0), 17.4-47.9 27.0 (5.0), 17.2-45.9 27.2 (5.0), 17.2-47.9
Mean (SD) duration of diabetes (years), range 18.5 (12.9), 1.1-56.9 17.5 (12.1), 1.1-51.9 18.0 (12.5), 1.1-56.9
Any macrovascular complication 68 (52) 79 (59) 147 (55)
Retinopathy 51 (39) 65 (48) 116 (43)
Neuropathy 13 (10) 6 (4) 19 (7)
Nephropathy:
 Present 26 (20) 24 (18) 50 (19)
 Not calculable 24 (18) 26 (19) 50 (19)
≥1 episodes of severe hypoglycaemia within past year 16 (12) 15 (11) 31 (12)
HbA1c 7.5% 119 (90) 123 (91) 242 (91)
Mean (SD) HbA1c (%), range 9.3 (1.9), 5.7-16.7 9.0 (1.4), 6.1-14.1 9.1(1.7), 5.7-16.7
Mean (SD) HbA1c (mmol/mol), range 77.9 (21.0), 39.0-159.0 74.8 (15.6), 43.0-131.0 76.3 (18.5), 39.0-159.0
Total insulin dose (IU/weight) 128 (97) 133 (99) 261 (98)
Mean (SD) total insulin dose (IU/weight), range 0.72 (0.28), 0.20-1.53 0.75 (0.29), 0.28-1.99 0.74 (0.28), 0.20-1.99
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secondary outcomes
Hypoglycaemia
Relatively few severe hypoglycaemic episodes were 
observed post-baseline: 49 in 25 participants. The rate 
of severe hypoglycaemia during the 24 month follow-up 
did not differ between the treatment groups, adjusted 
for centre, course, baseline HbA1c, and presence of at 
least one severe hypoglycaemic episode in the 12 
months before baseline (incidence rate ratio 1.13, 95% 
confidence interval 0.51 to 2.51, P=0.77).
Across both treatment groups, the number of severe 
hypoglycaemic episodes was reduced. The average 
number of episodes for each patient per year in the 
study reduced from 0.17 before baseline to 0.10 during 
follow-up. The incidence rate ratio for the number of 
severe hypoglycaemic episodes in the 24 month fol-
low-up, compared with the year before baseline, was 
0.46 (0.24 to 0.89, P=0.02).
Across both treatment arms, on average, three moderate 
hypoglycaemic episodes were recorded for each patient 
over a four week history at six months. By 24 months this 
number was slightly lower (2.6 for pump group, 2.3 for 
multiple daily injections group) but there was no statisti-
cally significant difference between the groups in rates of 
moderate hypoglycaemic episodes at any time point.
Other biomedical outcomes
Body weight remained roughly constant throughout the 
study period, and was not statistically significantly 
 different between the treatment groups at any time 
point (table 4 ). A slight increase in high density lipo-
protein cholesterol and a slight decrease in total choles-
terol levels were observed in both groups, with no 
evidence of a difference between treatment groups in 
change from baseline (P values ranged from 0.22 to 
0.86). Insulin dose decreased in both arms. At 12 
months, participants in the pump group had a 0.07 IU/
kg greater reduction in insulin dose than those in the 
multiple daily injections group (95% confidence inter-
val 0.01 to 0.13 decrease, P=0.02). The difference was 
slightly smaller at six and 24 months and was not statis-
tically significant. There was no statistically significant 
difference in the odds of proteinuria between the treat-
ment groups at any time point (table 5).
Diabetic ketoacidosis
The number or type of serious adverse events did not 
differ between the groups, with the exception of dia-
betic ketoacidosis, which was greater in the pump 
group compared with multiple daily injections group 
(17 v 5). More patients using pumps than using multiple 
daily injections had several episodes (5 v 2) and the dif-
ferences were confined to the first year, with four epi-
sodes in each group during the second year. Three 
episodes occurred in two participants who switched to 
pump treatment, and one in a participant who switched 
to multiple daily injections. Most episodes of ketoacido-
sis were caused by infections and 18% by set failure in 
those using pumps. Only five episodes occurred when 
participants implemented all sick day rules.
Ancillary outcomes
High levels of completion of the psychosocial question-
naires were observed across all questionnaires and time 
points (around 90% completed at each time point). The 
completion rate was slightly higher for participants 
allocated to the pump compared with multiple daily 
injections, which reflects the relative dropout rates in 
the two groups. No between group differences were 
found in the generic quality of life and health status 
instruments SF-12, WHOQOL-BREF, and EQ-5D, and the 
HADs score for depression and anxiety at six, 12, and 24 
months (tables 6-8).
The overall diabetes specific quality of life (DSQOL) 
(on a 100 point scale) showed that both groups 
improved at 24 months, by a mean of 8.2 (SD 13.1) points 
in the pump group and 4.2 (SD 13.2) points in the multi-
ple daily injections group. Both groups showed 
improvements in the DSQOL subdomains, which were 
greater in the pump group although not always reach-
ing statistical significance.
The improvement in DSQOL diet restrictions was 
larger for the pump group compared with multiple daily 
injections group at both 12 and 24 months (12 month 
adjusted mean difference in change from baseline −4.1 
(95% confidence interval −7.2 to −1.0, P=0.01); 24 month 
adjusted mean difference in change from baseline −5.1 
(−8.6 to −1.6, P=0.004); lower scores represent better 
outcomes. The pump group also had greater improve-
ment in DSQOL daily hassle or functions at both 12 and 
table 2 | Proportion of participants with Hba1c ≤7.5% (58 mmol/mol) at six, 12, and 24 
months (including all participants regardless of baseline Hba1c)
Follow-up
Pump treatment 
(n/n (%))
Multiple daily 
injections (n/n (%)) Odds ratio* (95% Ci) P value
6 months 26/132 (20.5) 26/123 (21.1) 1.03 (0.51 to 2.10) 0.93
12 months 29/126 (23.0) 27/120 (22.5) 1.32 (0.62 to 2.80) 0.48
24 months 32/128 (25.0) 28/120 (23.3) 1.22 (0.62 to 2.39) 0.57
table 3 | Mean difference in change in Hba1c (%) at six and 12 months in participants 
with baseline Hba1c ≥7.5%
Follow-up
Pump treatment Multiple daily injections Mean difference in 
change* (95% Ci) P valueno Mean (sD) change no Mean (sD) change
6 months 118 −0.76 (1.19) 111 −0.36 (1.06) −0.25 (−0.52 to 0.02) 0.07
12 months 111 −0.70 (1.10) 107 −0.40 (1.02) −0.13 (−0.40 to 0.14) 0.35
*Adjusted for baseline HbA1c, centre, and course, using mixed effects regression model.
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Fig 2 | Mean change (%) in glycated haemoglobin (Hba1c) 
over time in participants with baseline Hba1c ≥7.5% (58 
mmol/mol) (including only participants with data at all four 
time points, n=208). MDi=multiple daily injections
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24 months; at 24 months the score had decreased by 
10 points in the pump group, compared with 4 points in 
the multiple daily injections group (adjusted mean dif-
ference −6.3, −10.9 to −1.8, P=0.01).
Participants in the pump group had better improve-
ment in treatment satisfaction at all time points (table 
9) but the difference was statistically significant at 12 
and 24 months only (P=0.07 at six months, P<0.001 at 12 
and 24 months).
retrospective analyses
Participants achieving the updated NICE 
recommendation of HbA1c ≤6.5%
A retrospective analysis showed that eight (3%) of all 
participants (4/128 pump group and 4/120 multiple daily 
injections group) reached an HbA1c of ≤6.5% (47 mmol/
mol) after two years (table 10). Of these, two participants 
(both in the pump group) experienced one or more epi-
sodes of severe hypoglycaemia during follow-up.
Participant contacts
A retrospective analysis showed that, on average, those 
allocated to pumps had around double the number of 
contacts with professionals for diabetes between base-
line and the end of year 1, both face to face and by tele-
phone. Between months 12 and 24, those using pumps 
had more face-to-face contacts, which were of longer 
duration (mean 1.6 v 1.3 contacts), but fewer telephone 
contacts (0.7 v 1.2).
Blood glucose testing
A retrospective analysis indicated that there was no dif-
ference in the mean frequency of blood glucose testing 
between treatment groups at 24 months after adjust-
ment for baseline number of blood glucose tests, centre, 
and DAFNE course. The adjusted mean difference in 
blood glucose tests was 0.22 (95% confidence interval 
−0.24 to 0.68) per day or 3.1 (−3.4 to 9.6) over two weeks; 
P=0.35. Overall, the number of blood glucose tests 
increased from 3.6 per day at baseline to 4.1 per day at 
24 months (95% confidence interval 0.33 to 0.82, 
P<0.001).
Subgroup analysis
A retrospective analysis found no reliable statistical evi-
dence of any subgroup effects or interactions between 
group (figs 3  and 4). However, there was some indica-
tion that participants with qualifications up to A level or 
equivalent did better in the pump group than in the 
multiple daily injections group (mean difference in 
HbA1c change (%) at 24 months −0.7% (95% confidence 
interval −1.2% to −0.1%) (−7.4 mmol/mol, 95% confi-
dence interval −13.2 to −1.5)), although the interaction 
test was not statistically significant (P=0.07).
discussion
In a group of adults with type 1 diabetes referred for 
structured training in flexible insulin treatment because 
table 4 | secondary continuous outcomes: mean difference in change from baseline at six, 12, and 24 months
Outcome
Pump treatment
Multiple daily 
injections
adjusted difference* 
(95% Ci) P valueno Mean (sD) change no
Mean (sD) 
change
Body weight (kg):
 6 months 131 −0.05 (4.35) 124 −0.61 (4.32) 0.45 (−0.66 to 1.55) 0.43
 12 months 123 0.78 (4.95) 116 −0.05 (4.65) 0.67 (−0.64 to 1.98) 0.32
 24 months 127 0.71 (5.45) 117 0.20 (6.37) 0.42 (−1.17 to 2.01) 0.61
HDL cholesterol (mmol/L):
 6 months 123 0.01 (0.28) 116 0.04 (0.36) −0.05 (−0.13 to 0.03) 0.26
 12 months 109 0.04 (0.29) 113 0.04 (0.38) −0.01 (−0.10 to 0.08) 0.80
 24 months 117 0.03 (0.30) 112 0.06 (0.39) −0.04 (−0.12 to 0.05) 0.43
Cholesterol (mmol/L):
 6 months 130 −0.17 (0.84) 122 −0.01 (0.84) −0.14 (−0.35 to 0.08) 0.22
 12 months 121 −0.14 (1.02) 116 −0.08 (0.83) −0.02 (−0.26 to 0.22) 0.86
 24 months 127 −0.21 (0.95) 116 −0.19 (1.03) 0.03 (−0.25 to 0.30) 0.85
Total insulin dose (IU/weight):
 6 months 130 −0.07 (0.27) 124 −0.03 (0.21) −0.04 (−0.10 to 0.02) 0.20
 12 months 123 −0.09 (0.26) 117 −0.02 (0.22) −0.07 (−0.13 to −0.01) 0.02
 24 months 125 −0.06 (0.27) 116 −0.01 (0.23) −0.05 (−0.11 to 0.02) 0.15
HDL=high density lipoprotein.
*Adjusted for centre, course, and baseline HbA1c value.
table 5 | secondary outcomes: proportion of participants in each proteinuria category (as 
defined by albumin to creatinine ratio) at six, 12, and 24 months. values are numbers 
(percentages) unless stated otherwise
Proteinuria category by follow-up
Pump 
treatment
Multiple daily 
injections Odds ratio* (95% Ci) P value
6 months:
 Normal 76 (80) 81 (81)
0.79 (0.36 to 1.73) 0.56 Microalbuminuria 17 (18) 14 (14)
 Macroalbuminuria 2 (2) 5 (5)
12 months:
 Normal 65 (76) 67 (81)
1.14 (0.53 to 2.48) 0.74 Microalbuminuria 16 (19) 10 (12)
 Macroalbuminuria 5 (6) 6 (7)
24 months:
 Normal 77 (81) 70 (83)
1.04 (0.46 to 2.32) 0.93 Microalbuminuria 16 (17) 9 (11)
 Macroalbuminuria 2 (2) 5 (6)
*Adjusted for centre, course, and baseline HBA1c value.
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of suboptimal diabetes control, participation in the 
REPOSE trial achieved a clinically worthwhile decrease 
in HbA1c of 0.6% (7 mmol/mol) at two years in those 
with a baseline HbA1c of >7.5%. However, in terms of 
the primary outcomes, there were no statistically signif-
icant differences in change from baseline to 24 months 
between those randomised to pump treatment or those 
using multiple daily injections, nor in the proportion of 
participants reaching an HbA1c of ≤7.5%, indicating 
that pump treatment provided no clear biomedical ben-
efit over training in DAFNE skills.
Rates of severe hypoglycaemia were halved in both 
groups (despite lower HbA1c values), a benefit main-
tained to 24 months with no difference between the 
groups in this or in rates of moderate hypoglycaemia. 
There were no other differences in biomedical outcomes 
apart from slightly greater reductions in insulin doses 
in those randomised to pump treatment. Both groups 
showed improved satisfaction with treatment and dia-
betes specific quality of life. Treatment satisfaction and 
two subdomains of the diabetes specific quality of life 
scale improved to a greater extent at two years in those 
allocated to pump treatment.
strengths and limitations of this study
Compared with previous trials of pump treatment our 
study had a robust, multisite design, involved much 
larger numbers, and had a clinically meaningful period 
of follow-up pump treatment. Participants in both 
groups used analogue insulins and bolus calculators. 
The study was conducted in experienced secondary 
care centres and involved attendance at a structured 
education intervention that is well established across 
the UK. It included a comprehensive psychological eval-
uation with high levels of data completeness. The prag-
matic study design thus provides good external validity, 
particularly as participating in the educational course 
led to sustained improvements in glycaemic control and 
reduced rates of severe hypoglycaemia.
It is not possible to blind a trial where insulin delivery 
systems are fundamentally different and this imposes 
limitations on any randomised controlled trial involv-
ing pumps. However, for the primary outcomes, HbA1c 
was objectively assessed using a central laboratory.17 A 
trial studying people who have expressed a desire for 
pump treatment is likely to struggle to recruit 
 participants if one arm continues to use multiple daily 
injections. Those randomised to the injections arm 
might also either drop out or exhibit poor outcomes 
because of “disappointment” and lack of motivation. 
We recruited individuals who had not specifically 
requested pump treatment but were awaiting a course 
in diabetes self management to help them improve their 
metabolic control. Thus, our aim was to determine any 
added benefit of pumps over multiple daily injections 
while controlling for the training itself.
A potential limitation is that those randomised to 
pump treatment might have been insufficiently 
table 6 | Mean difference in change of psychosocial outcomes from baseline to six months
Outcomes
Pump treatment
Multiple daily 
injections
adjusted difference* 
(95% Ci) P valueno
Mean (sD) 
change no
Mean (sD) 
change
SF-12 physical component summary† 127 1.2 (6.1) 116 0.5 (8.6) 0.3 (−1.4 to 2.0) 0.72
SF-12 mental component summary 127 0.2 (8.8) 117 0.9 (9.9) −0.8 (−2.9 to 1.3) 0.45
DSQOL:
 Total score† 128 −5.2 (12.2) 117 −4.4 (11.2) −0.1 (−2.8 to 2.6) 0.94
 Social relations 128 −2.2 (11.8) 117 −3.0 (13.2) 1.5 (−1.2 to 4.2) 0.28
 Leisure time restrictions and flexibility 128 −5.1 (16.6) 117 −4.4 (18.5) −0.1 (−3.8 to 3.7) 0.97
 Physical complaints 128 −6.0 (17.0) 117 −4.8 (13.8) −0.1 (−3.5 to 3.3) 0.95
 Worries about the future 128 −7.9 (20.4) 117 −7.5 (19.4) −0.7 (−5.5 to 4.1) 0.78
 Daily hassle of functions 128 −6.3 (18.9) 117 −5.0 (18.7) −0.8 (−5.0 to 3.4) 0.70
 Diet restrictions 128 −11.3 (18.3) 117 −6.4 (16.0) −3.3 (−6.9 to 0.2) 0.06
 Treatment satisfaction (PWTSS)† 118 2.1 (4.4) 109 2.1 (4.8) 0.1 (−0.7 to 1.0) 0.79
WHOQOL-BREF:
 Physical health† 127 0.4 (2.3) 117 0.2 (2.3) 0.1 (−0.4 to 0.6) 0.74
 Psychological 128 0.1 (1.9) 117 0.4 (2.2) −0.3 (−0.7 to 0.2) 0.23
 Social relationships 127 −0.3 (2.7) 117 0.3 (3.0) −0.7 (−1.3 to 0.1) 0.03
 Environment 128 0.1 (1.7) 117 0.4 (1.6) −0.3 (−0.7 to 0.1) 0.17
HFS behaviour score‡ 127 −1.7 (4.9) 117 −0.2 (4.8) −0.9 (−2.0 to 0.1) 0.07
HFS worry score§ 128 −4.0 (10.9) 117 −2.8 (9.5) −0.1 (−2.4 to 2.1) 0.91
HADS anxiety score¶ 128 −0.2 (3.0) 117 −0.6 (3.3) 0.4 (−0.3 to 1.1) 0.26
HADS depression score 128 −0.3 (2.9) 117 −0.2 (2.5) 0.1 (−0.5 to 0.7) 0.74
EQ-5D** 127 −0.02 (0.17) 117 −0.01 (0.18) −0.02 (−0.06 to 0.02) 0.38
SF12=12 item short form health survey; DSQOL=diabetes specific quality of life; PWTSS=preference weighted treatment satisfaction score; WHOQOL-
BREF=World Health Organization quality of life-BREF; HFS=hypoglycaemia fear survey; HADS=hospital anxiety and depression scale; EQ-5D=EuroQol 
five dimensions questionnaire.
*Calculated using mixed effects regression adjusted for baseline quality of life score, centre, course, and baseline HBA1c.
†Scored from 0 (poor) to 100 (good).
‡Scored from 10 to 50 (higher score=greater fear).
§Scored from 17 to 85 (higher score=greater fear).
¶Scored from 0 (good) to 21 (poor).
**Scale from −0.56 to 1.00 (good health).
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 motivated to make the most of any technological benefit 
since they had not expressed a particular wish to use a 
pump. A common reason given by patients for not 
wanting to participate in REPOSE was reluctance to use 
an insulin pump. However, educators encouraged par-
ticipants to use additional technological pump features 
(eg using more sophisticated bolus delivery) and pro-
vided extra input when this training was requested. 
Overall, we reasoned that since participants had signed 
up for a course to improve their glucose control, any 
added benefits of pump treatment would emerge.
In this pragmatic trial we did not collect detailed 
information about pump basal rates, how often patients 
adjusted and tested these, and time spent with pump 
participants. Our study was not designed to establish 
which features of pumps determine success in lowering 
HbA1c values in those doing “well” with pump treat-
ment. An explanatory trial would have required a differ-
ent study design. We therefore cannot be sure why 
those allocated to pump treatment failed to show a 
greater decrease in HbA1c.
We recorded the average number of blood glucose 
tests each day in both groups over the previous two 
weeks, both at baseline and at 24 months. Both groups 
had increased the number of daily tests from 3.6 before 
training to more than four each day at 24 months, but 
this did not differ between the groups. Perhaps this fre-
quency of testing reflects a level of engagement in self 
management that was insufficient for participants in 
the pump group to take full advantage of the technol-
ogy. One interpretation was that the educators were 
unable to provide adequate training in use of the pump 
during the one week course. However, it is just as likely 
that provision of pump treatment in a group of patients 
who had not been previously trained in delivery of flex-
ible intensive insulin treatment included many who 
subsequently found it too challenging to implement 
and maintain the intensity of self management that 
both pump treatment and multiple daily injections 
demand.
Comparison with other trials
Two appraisals of pumps by NICE have reviewed the 
evidence on clinical and cost effectiveness. One18  noted 
that there were no trials of pumps against “best multi-
ple daily injections” with long acting and short acting 
analogue insulins; that some trials had unequal 
amounts of education in the arms (with more in the 
pump arms); and that the trials had focused on easily 
measurable outcomes such as HbA1c, rather than on 
benefits in terms of flexibility of lifestyle and quality of 
life. The report recommended trials of pumps against 
analogue based multiple daily injections. A more recent 
report19 found only three trials in adults, one a pilot and 
the other involving 39 adults with type 1 diabetes, 
already using pump treatment who were randomised to 
continue with the pump or to switch to glargine based 
multiple daily injections. Patients received four months 
table 7 | Mean difference in change in quantitative psychosocial outcomes (from baseline to 12 months
Outcomes
Pump treatment
Multipe daily 
injections
adjusted difference* 
(95% Ci) P valueno
Mean (sD) 
change no
Mean (sD) 
change
SF-12 physical component summary† 119 0.7 (7.7) 115 1.1 (6.9) −0.4 (−2.1 to 1.3) 0.67
SF-12 mental component summary 121 −1.1 (10.8) 116 −1.0 (10.9) −0.1 (−2.6 to 2.3) 0.91
DSQOL:
 Total score† 121 −5.8 (11.4) 116 −3.6 (10.1) −1.5 (−4.0 to 1.1) 0.25
 Social relations 121 −2.9 (12.4) 116 −1.5 (11.2) −0.7 (−3.6 to 2.1) 0.62
 Leisure time restrictions and flexibility 121 −5.2 (17.7) 115 −4.5 (15.9) −0.0 (−3.8 to 3.7) 0.98
 Physical complaints 121 −5.6 (15.2) 115 −4.4 (13.0) −0.4 (−3.5 to 2.8) 0.82
 Worries about the future 121 −8.1 (21.7) 116 −6.4 (20.9) −2.0 (−7.0 to 2.9) 0.42
 Daily hassle of functions 121 −9.1 (19.4) 116 −3.5 (18.7) −5.0 (−9.2 to −0.8) 0.02
 Diet restrictions 121 −12.8 (17.1) 115 −7.0 (16.7) −4.1 (−7.2 to −1.0) 0.01
 Treatment satisfaction (PWTSS) † 109 1.5 (4.6) 112 1.4 (4.4) 0.1 (−0.8 to 1.0) 0.84
WHOQOL-BREF:
 Physical health† 121 0.0 (2.0) 116 0.1 (2.2) −0.1 (−0.6 to 0.4) 0.60
 Psychological 121 −0.1 (1.9) 116 0.1 (2.0) −0.2 (−0.7 to 0.2) 0.34
 Social relationships 121 −0.2 (3.0) 116 −0.1 (2.5) −0.3 (−0.9 to 0.4) 0.38
 Environment 121 0.2 (1.7) 116 0.3 (1.7) −0.1 (−0.5 to 0.3) 0.73
HFS behaviour score‡ 120 −1.2 (5.2) 116 −0.1 (5.1) −1.0 (−2.1 to 0.2) 0.09
HFS worry score§ 121 −4.3 (12.5) 116 −3.3 (10.7) −0.6 (−3.1 to 1.8) 0.60
HADS anxiety score¶ 121 −0.1 (3.2) 116 −0.3 (3.1) 0.2 (−0.6 to 0.9) 0.66
HADS depression score 121 −0.3 (3.3) 116 0.4 (2.9) −0.5 (−1.2 to 0.2) 0.18
EQ-5D** 120 −0.03 (0.15) 113 −0.02 (0.17) −0.00 (−0.04 to 0.04) 0.88
SF12=12 item short form health survey; DSQOL=diabetes specific quality of life; PWTSS=preference weighted treatment satisfaction score; WHOQOL-
BREF=World Health Organization quality of life-BREF; HFS=hypoglycaemia fear survey; HADS=hospital anxiety and depression scale; EQ-5D=EuroQol 
five dimensions questionnaire.
*Calculated using mixed effects regression adjusted for baseline quality of life score, centre, course, and baseline HBA1c.
†Scored from 0 (poor) to 100 (good).
‡Scored from 10 to 50 (higher score=greater fear).
§Scored from 17 to 85 (higher score=greater fear).
¶Scored from 0 (good) to 21 (poor).
**Scale from −0.56 to 1.00 (good health).
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treatment with each. A third trial recruited 57 adults 
randomised to pump or analogue injections in an 
equivalence study. None showed any difference in 
HbA1c. Thus, the evidence base from trials for compar-
ing pumps and “best multiple daily injections” was 
weak in terms of numbers, with a total of only 103 
patients and short follow-up.
The assessment for the second appraisal19 reviewed 
observational studies of adults switching to pumps for 
clinical indications. These have the advantage of mea-
suring change in glycaemic control and hypoglycae-
mia in those who have most to gain, and these studies 
showed improved HbA1c of the order of around 0.5%. 
Bias in observational studies is more of a problem, and 
results must be treated with caution. Furthermore, of 
48 observational studies, only nine reported quality of 
life. Study numbers were small, with at most 35 
patients. Duration was usually short. The longest 
table 8 | Mean difference in quantitative psychosocial outcomes from baseline to 24 months
Outcomes
Pump treatment
Multiple daily 
injections
adjusted difference* 
(95% Ci) P valueno
Mean (sD)  
change (sD) no
Mean (sD) 
change
SF-12 physical component summary† 122 0.3 (7.9) 112 1.0 (8.3) −0.4 (−2.1 to 1.3) 0.66
SF-12 mental component summary 123 2.1(11.2) 114 0.5 (10.3) 1.6 (−0.7 to 4.0) 0.18
DSQOL:
 Total score† 123 −8.2 (13.1) 114 −4.2 (13.2) −3.8 (−6.5 to −1.1) 0.01
 Social relations 123 −5.7 (12.9) 113 −2.7 (14.8) −2.5 (−5.4 to 0.4) 0.09
 Leisure time restrictions and flexibility 123 −8.1 (17.0) 113 −3.6 (19.7) −4.6 (−8.4 to −0.9) 0.02
 Physical complaints 123 −8.7 (17.2) 113 −4.8 (16.6) −3.6 (−7.3 to −0.0) 0.05
 Worries about the future 123 −11.9 (23.3) 113 −7.8 (21.2) −4.8 (−9.7 to 0.2) 0.06
 Daily hassle of functions 123 −9.6 (21.2) 113 −3.6 (21.5) −6.3 (−10.9 to −1.8) 0.01
 Diet restrictions 123 −12.8 (19.5) 113 −6.9 (19.3) −5.1 (−8.6 to −1.6) 0.004
 Treatment satisfaction (PWTSS) † 113 1.9 (4.5) 108 1.5 (5.4) 0.5 (−0.5 to 1.4) 0.32
WHOQOL-BREF:
 Physical health† 123 0.5 (2.4) 114 −0.1 (2.2) 0.5 (−0.0 to 1.0) 0.07
 Psychological 123 0.5 (2.5) 114 0.3 (2.4) 0.2 (−0.4 to 0.7) 0.57
 Social relationships 123 0.0 (3.3) 114 0.1 (2.9) −0.2 (−0.9 to 0.5) 0.63
 Environment 122 0.4 (2.2) 114 0.3 (2.0) 0.3 (−0.2 to 0.8) 0.21
HFS behaviour score‡ 122 −1.4 (5.6) 114 −0.6 (5.1) −0.4 (−1.5 to 0.7) 0.44
HFS worry score§ 123 −6.7 (13.0) 114 −2.9 (12.5) −3.4 (−6.0 to −0.8) 0.01
HADS anxiety score¶ 123 −1.0 (4.0) 114 −0.5 (3.5) −0.5 (−1.3 to 0.4) 0.26
HADS depression score 123 −1.0 (3.8) 114 −0.2 (3.3) −0.7 (−1.5 to 0.1) 0.11
EQ-5D** 123 −0.00 (0.18) 113 −0.02 (0.18) 0.02 (−0.03 to 0.06) 0.46
SF12=12 item short form health survey; DSQOL=diabetes specific quality of life; PWTSS=preference weighted treatment satisfaction score; WHOQOL-
BREF=World Health Organization quality of life-BREF; HFS=hypoglycaemia fear survey; HADS=hospital anxiety and depression scale; EQ-5D=EuroQol 
five dimensions questionnaire.
*Calculated using mixed effects regression adjusted for baseline quality of life score, centre, course, and baseline HBA1c.
†Scored from 0 (poor) to 100 (good).
‡Scored from 10 to 50 (higher score=greater fear).
§Scored from 17 to 85 (higher score=greater fear).
¶Scored from 0 (good) to 21 (poor).
**Scale from −0.56 to 1.00 (good health).
table 9 | ancillary outcomes: diabetes treatment satisfaction questionnaire change from baseline at six and 24 months, questionnaire raw scores at 12 
months
Outcomes
Pump treatment Multiple daily injections
Difference*(95% Ci) P valueno Median (interquartile range) no Median (interquartile range)
6 months:
 Perceived frequency† of hyperglycaemia 126 −1 (−2 to 0) 116 −1 (−2 to 1) −0.0 (−1.0 to 0.0) 0.18
 Perceived frequency† of hypoglycaemia 127 0 (−1 to 1) 116 −1 (−2 to 0) 0.0 (−0.0 to 1.0) 0.30
 Treatment satisfaction (scores 0 to 36)‡ 126 8 (3 to 12) 116 5 (1 to 10) 2.0 (1.0 to 4.0) 0.07
12 months:
 Perceived change in frequency of hyperglycaemia 121 0 (−2 to 1) 118 1 (−1 to 2) 0.0 (−0.0 to 1.0) 0.13
 Perceived change in frequency§ of hypoglycaemia 121 −1 (−2 to 0) 118 −1 (−2 to 0) 0.0 (−0.0 to 1.0) 0.35
 Treatment satisfaction (change) (scores −18 to 18)‡ 121 16 (13 to 18) 118 12 (7 to 16) −3.0 (−4.0 to −1.0) <0.001
24 months:
 Perceived frequency† of hyperglycaemia 122 −1 (−2 to 0) 113 −1 (−2 to 0) −0.0 (−1.0 to 0.0) 0.07
 Perceived frequency† of hypoglycaemia 123 0 (−1 to 1) 113 0 (−2 to 0) 0.0 (−0.0 to 1.0) 0.50
 Treatment satisfaction‡ 122 8 (3 to 12) 113 5 (0 to 9) 4.0 (2.0 to 5.0) <0.001
*95% confidence interval for median difference calculated as described in Newson.16 Calculated using Wilcoxon-Mann-Whitney U test.
†Scored from 0 (infrequent) to 6 (frequent).
‡Higher scores represent better outcomes.
§Scored from −3 (less often) to 3 (more often).
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study noted that initial benefits from pump treatment 
might not be sustained. The present study has thus 
addressed several of these concerns with large num-
bers in an adequately powered trial and a virtually 
complete dataset for both biomedical and psychologi-
cal outcomes.
Clinical and policy implications
Our study suggests that extending the availability of 
pumps to adults with type 1diabetes with suboptimal 
glycaemic control and no desire to use this form of insu-
lin delivery is unlikely to result in either lower levels of 
glycaemia as measured by HbA1c or lower rates of 
hypoglycaemia. The absence of a control arm in which 
structured training was not provided, means we cannot 
be certain that participation in training explains the 
considerable decreases in HbA1c and severe hypogly-
caemia in both groups. Yet, it seems unlikely that mere 
trial participation led to sustained decreases in HbA1c 
and severe hypoglycaemia for up to two years, particu-
larly as allocation to such a control arm, in previous 
trials involving the DAFNE intervention, showed no 
effect on HbA1c.2
The results would appear to support the current clin-
ical pathway as proposed by NICE, in which people 
desiring improved diabetes control undergo structured 
training in flexible insulin treatment with multiple 
daily injections alone. The trial outcomes, together with 
the review for NICE of observational pump studies, sug-
gest that pumps might usefully be reserved to support 
those who actively engage in self management after 
structured education. Those who find that despite their 
best efforts, injections fail to deliver the expected bene-
fits could then be offered the additional technological 
advantages of an insulin pump.
Clearly some patients improved more than others in 
terms of glucose control or hypoglycaemia and we 
explored whether there were any demographic differ-
ences in those who did particularly well. There was no 
reliable evidence of any plausible subgroup effects or 
interactions between the pump and multiple daily 
injections group, and the baseline characteristics of 
those whose glycaemic control changed to <7.5% during 
the trial were no different from the pump population as 
a whole. We observed modest centre effects but no sys-
tematic differences according to greater experience in 
pump treatment.
Those using insulin pumps did show some quality of 
life benefits, reporting less restriction in diet and daily 
hassles in the DSQOL scale and greater treatment satis-
faction. Nevertheless, the differences were modest and 
observed in comparison with a group given no novel 
technology. Since they were not associated with other 
positive treatment outcomes, those observations are 
probably insufficient to justify a major alteration in 
guidelines for the use of pumps.
One of the more striking results of this trial was the 
generally high level of HbA1c among adults in the UK 
enrolling for self management training in flexible insulin 
treatment. Participation in the courses produced import-
ant and sustained decreases, but for most participants 
still fell well short of the target recommended by NICE, 
recently reduced from 7.5% to 6.5%.20  The high levels of 
HbA1c among people with type 1 diabetes in UK centres 
compared with most other European countries have also 
been noted in a recent study.21  There is an urgent need to 
explore the barriers to successful self management in 
adults with type 1 diabetes in the UK and to understand 
why referral for appropriate training is often left so long. 
This was also the conclusion of our recently completed 
research programme.15 Our results suggest that these 
problems cannot be overcome merely by providing addi-
tional technology in the form of pumps.
table 10 | number and proportion of participants 
achieving new national institute for Health and Care 
excellence Hba1c recommendation of ≤6.5% at six, 12, 
and 24 months
Follow-up
Pump treatment 
(n/n (%))
Multiple daily 
injections (n/n (%))
6 months 3/132 (2.3) 2/123 (1.6)
12 months 3/126 (2.4) 3/120 (2.5)
24 months 4/128 (3.1) 4/120 (3.3)
Number of participants achieving ≤6.5% is small and hence statistical 
models to estimate difference in proportions and confidence intervals 
failed to converge.
Sex
  Male
  Female
Level of education
  Up to A-level/equivalent
  Vocational/beyond A-level
IMD
  IMD below median
  IMD above median
SIMD
  SIMD below median
  SIMD above median
Age (years)
  <35
  35-49
  ≥50
BMI (kg/m2)
  Normal/<25
  Overweight/25-29.9
  Obese/≥30
ONS occupational status
  Level 1
  Level 2
  Level 3
  Level 4
-0.2 (-0.6 to 0.2)
-0.4 (-0.9 to 0.1)
-0.7 (-1.2 to -0.1)
-0.1 (-0.5 to 0.3)
-0.2 (-1.0 to 0.5)
-0.2 (-0.7 to 0.3)
-0.5 (-1.3 to 0.2)
-0.1 (-0.8 to 0.7)
-0.5 (-1.1 to 0.0)
-0.2 (-0.6 to 0.3)
-0.2 (-0.8 to 0.4)
-0.1 (-0.6 to 0.4)
-0.4 (-0.9 to 0.1)
-0.4 (-1.0 to 0.3)
-0.4 (-1.1 to 0.3)
-0.2 (-0.7 to 0.4)
-0.4 (-0.9 to 0.2)
-0.1 (-1.0 to 0.9)
-0.75-1.00-1.25-1.50 -0.50 -0.25
Minimal clinically important dierenceEnglish IMD, 2010 
Scottish IMD, 2012
0 0.25 0.50 0.75
Characteristic
Favours pump Favours MDI
Di erence
(95% CI)
Di erence
(95% CI)
Fig 3 | Mean difference in Hba1c change (%) at 24 months for pump versus multiple daily 
injections by subgroup. MCiD=minimal clinically important difference; iMD=index of 
multiple deprivation; Ons=Office for national statistics occupational status from level 1, 
elementary trade, service, administration roles, to level 4, corporate managers or 
directors, research, teaching, business, and public service higher level professionals
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Conclusions
People with type 1 diabetes might be better served by 
ensuring far greater availability of high quality, struc-
tured self management training, which is currently only 
accessed by around 10% of adults in the UK.22 Partici-
pants might only recognise the limitations of insulin 
delivery by multiple daily injections if they start actively 
managing their diabetes after training. Those individu-
als could then be offered pump treatment to help them 
reach the stringent glucose targets necessary to achieve 
an HbA1c of 6.5% or to overcome problematic hypogly-
caemia.
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